Intranasally administrated fusion-inhibitory lipopeptides derived from the SARS-CoV-2 spike protect mice from different viral variants and induce cross-reactive immunity, offering a innovative antiviral approach against COVID-19
- Said Mougari
- Valérie Favède
- Branka Horvat